Alnylam Pharmaceuticals Inc

NASDAQ:ALNY   3:59:58 PM EDT
223.31
-7.43 (-3.22%)
Other Pre-Announcement

Alnylam Pharmaceuticals Reports Q2 Net Loss of $2.29 Per Share

Published: 07/28/2022 12:21 GMT
Alnylam Pharmaceuticals Inc (ALNY) - Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity.
Qtrly Net Product Revenues of $214 Million for Onpattro, Givlaari, and Oxlumo (33% Growth Versus.
Same Period Last Year).
Alnylam Pharmaceuticals - Received FDA Approval of Amvuttra for Treatment of Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis in Adults.
Reiterated 2022 Financial Guidance.
Qtrly GAAP Net Loss per Common Share - Basic and Diluted$2.29.
Qtrly Non-GAAP Net Loss per Common Share - Basic and Diluted $2.03.
Q2 Earnings per Share View $-1.63, Revenue View $255.9 Million -- Refinitiv Ibes Data (analyst estimates).
FY2022 Earnings per Share View $-6.82, Revenue View $1.09 Billion -- Refinitiv Ibes Data (analyst estimates).